Truist rates BioNTech a Buy, citing its shift to oncology with BNT327 leading the way. Key data updates and growth catalysts ...

Research analysts at StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS – Get Free Report) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the ...